Bank Of America Upgrades Sarepta Therapeutics On 'Increased Conviction' Of Drug Approval

By: via Benzinga
Bank of America upgraded Sarepta Therapeutics Inc (NASDAQ: SRPT) from Neutral to Buy on Tuesday and raised its price target from $19 ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.